NASDAQ:MGRX Mangoceuticals (MGRX) Stock Price, News & Analysis $0.12 -0.01 (-7.55%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$0.13 +0.01 (+4.37%) As of 11/20/2026 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Mangoceuticals Stock (NASDAQ:MGRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mangoceuticals alerts:Sign Up Key Stats Today's Range$0.12▼$0.1450-Day Range$0.12▼$0.4852-Week Range$0.12▼$1.38Volume241,104 shsAverage Volume839,877 shsMarket Capitalization$2.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Mangoceuticals, Inc. is a men’s health and wellness company that offers telehealth services through its online platform. The platform connects customers with healthcare providers for consultations and, when appropriate, prescription treatments.The company’s offerings have included treatments for erectile dysfunction, hair loss and testosterone-related concerns, as well as weight-management services. Prescriptions are fulfilled through pharmacy partners.Mangoceuticals primarily serves customers in the United States through its digital platform.AI Generated. May Contain Errors. Read More Mangoceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks16th Percentile Overall ScoreMGRX MarketRank™: 0.80950378469 of 5 starsMangoceuticals scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingMangoceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageMangoceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Mangoceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mangoceuticals is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mangoceuticals is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMangoceuticals has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.29% of the float of Mangoceuticals has been sold short.Short Interest Ratio / Days to CoverMangoceuticals has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mangoceuticals has recently decreased by 41.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMangoceuticals does not currently pay a dividend.Dividend GrowthMangoceuticals does not have a long track record of dividend growth. News and Social Media0.7 / 5News SentimentN/A News SentimentMangoceuticals has a news sentiment score of -0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mangoceuticals this week, compared to 2 articles on an average week. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mangoceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders16.00% of the stock of Mangoceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.72% of the stock of Mangoceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mangoceuticals' insider trading history. Receive MGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mangoceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MGRX Stock News HeadlinesMangoceuticals Establishes Series D Preferred Stock DesignationNovember 13, 2026 | tipranks.comMangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X PlatformNovember 12, 2026 | globenewswire.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 22 at 1:00 AM | Porter & Company (Ad)Alignment Healthcare (NASDAQ:ALHC) and Mangoceuticals (NASDAQ:MGRX) Critical SurveyNovember 11, 2026 | americanbankingnews.comMangoceuticals Sets Combined 2025 and 2026 Shareholder MeetingNovember 6, 2026 | tipranks.comMangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market CloseOctober 9, 2026 | finance.yahoo.comMangoceuticals completes premium registered direct equity financingOctober 9, 2026 | tipranks.comMangoceuticals Secures $2.5 Mln Investment To Advance Antiviral IP CommercializationOctober 2, 2026 | rttnews.comSee More Headlines MGRX Stock Analysis - Frequently Asked Questions How have MGRX shares performed this year? Mangoceuticals' stock was trading at $0.74 on January 1st, 2026. Since then, MGRX stock has decreased by 83.3% and is now trading at $0.1236. How were Mangoceuticals' earnings last quarter? Mangoceuticals, Inc. (NASDAQ:MGRX) announced its earnings results on Monday, November, 16th. The company reported ($0.19) earnings per share (EPS) for the quarter. The company earned $69.50 thousand during the quarter. Mangoceuticals had a negative trailing twelve-month return on equity of 68.28% and a negative net margin of 3,679.33%. When did Mangoceuticals' stock split? Mangoceuticals's stock reverse split on the morning of Wednesday, October 16th 2024.The 1-15 reverse split was announced on Wednesday, October 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Mangoceuticals IPO? Mangoceuticals (MGRX) raised $5 million in an initial public offering on Tuesday, March 21st 2023. The company issued 1,300,000 shares at $4.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Mangoceuticals? Shares of MGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/16/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, MGRX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:MGRX CIK1938046 Webwww.mangoceuticals.com Phone833-626-4679FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.64 million Net Margins-3,679.33% Pretax Margin-3,679.67% Return on Equity-68.28% Return on Assets-62.66% Debt Debt-to-Equity RatioN/A Current Ratio1.28 Quick Ratio0.18 Sales & Book Value Annual Sales$315.23 thousand Price / Sales8.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book0.20Miscellaneous Outstanding Shares22,224,000Free Float18,668,000Market Cap$2.75 million OptionableNot Optionable Beta2.15 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:MGRX) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredA quick test most investors failCan you defend your biggest holding? Seeking Alpha Premium gives you its Quant valuation grade versus its sect...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mangoceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.